T o reduce the risk of coronary heart disease, the American Heart Association and other governmental and nongovernmental organizations have long recommended decreasing dietary saturated intakes and increasing intakes of n-6 polyunsaturated fatty acids (FA), up to 10% of dietary energy. Concerns still remain regarding high n-6 FA intakes and high n-6/n-3 FA ratios. 1 These concerns are related to in vitro and animal experiments showing that the n-6 essential FA, linoleic acid (the precursor of arachidonic acid), is the substrate of proinflammatory eicosanoids and cytokines. Recently, higher intakes of marine n-3 FA, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been described as having "positive" clinical benefits in reducing adverse outcomes relating to coronary heart disease morbidity and mortality. 2 However, a recent American Heart Association advisory 3 summarized a large body of evidence indicating that n-6 FA reduces inflammatory states, and are "protective" in decreasing the risk of coronary heart disease. In addition to lowering plasma low-density lipoprotein cholesterol levels, n-6 FA also has roles in lowering blood pressure and diminishing adverse factors relating to insulin resistance. 3
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Potential mechanisms of cardioprotective effects of n-3 FA are being defined because these bioactive molecules lower plasma triglyceride levels, decrease arrhythmias, lower blood pressure, impair platelet aggregation, and inhibit or block proinflammatory and other pathways associated with atherosclerosis and vulnerable plaques. 4 In animal models, n-3 FA-rich diets markedly decrease arterial low-density lipoprotein cholesterol deposition 5 in contrast to saturated fat-rich diets, which increase arterial wall cholesterol. 6 In addition to producing potent anti-inflammatory docosanoid catabolites, 7,8 n-3 FA may also be direct ligands for transcription factors 9 and/or may interact with specific receptors important in inflammatory cascades and insulin resistance, 10 pathways important in coronary heart disease. Of note, arachidonic acid also leads to synthesis of potent anti-inflammatory and proresolution lipoxins. 7 Not all intervention studies have shown the cardiovascular benefit of increased intakes of n-3 FA. This may relate, in part, to initial high baseline intakes in tissue levels of n-3 FA in certain populations (eg, Japanese individuals); short duration of interventions; small cohort sizes; a comparison of n-3 FA intervention studies using increasing intakes of ␣-linolenic acid (the essential FA precursor for EPA and DHA) with studies in which EPA and DHA are administered themselves; and studies that do not consider the baseline intakes of n-6 FA. Pischon et al 11 reported that dietary n-6 FA do not inhibit anti-inflammatory markers in humans and suggested that a combination n-3 and n-6 FA is associated with the lowest levels of inflammation. Therefore, should we address intake ratios or amounts to obtain optimal plasma and tissue levels of n-6 and n-3 FA?
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, the article by Wan et al 12 helps to understand the importance of n-6 and n-3 FA absolute levels and ratios in decreasing atherogensis in apolipoprotein (apo) E Ϫ/Ϫ mice. Rather than n-3 dietary or supplemental interventions to increase n-3 FA tissue levels, the experimental model described uses the transgenic fat-1 mouse model that is engineered to express the fat-1 gene from Caenorhabditis elegans, a gene absent in mammals. Originally described in the plant Arabidopsis, this gene encodes an n-3 FA desaturase that recognizes and converts a range of 18 to 20 carbon n-6 to n-3 FA. 13 Kang 14 and others have shown that fat-1 introduced into cell and animal models leads to higher levels of n-3 FA and lower ratios of n-6/n-3 FA in cells and tissues. In the article by Wan et al, fat-1 transgenic mice were bred with apoE Ϫ/Ϫ mice to obtain apoE Ϫ/Ϫ /fat-1 mice that resulted in markedly higher tissue levels of n-3 FA: this was associated with substantial reductions in n-6/n-3 FA ratios in plasma and other organs. Compared with apoE Ϫ/Ϫ mice, aortic lesion areas in apoE Ϫ/Ϫ /fat-1 mice decreased by approximately 50%. ApoE Ϫ/Ϫ /fat-1 mice had substantial reductions of proinflammatory markers and chemoattractant and adhesion molecules in plasma, aorta, and circulating monocytes.
Although most end points in the article by Wan et al 12 are compared with n-6/n3 plasma or tissue ratios, a close examination of the actual FA levels presented early in the Results section shows reductions in the levels of the numerator of the n-6/n-3 ratio, n-6 FA, by approximately 10% to 30%. However, increases in the absolute contributions of the denominator, n-3 FA, were between 500% and 800%. Thus, it is clear that the ratio is mainly controlled by increases in n-3 and not by decreases in n-6 FA. In the article by Wan et al and similar to what occurs in animal and human studies, major changes in n-6/n-3 ratios are largely controlled by changes in n-3 FA levels. 15 The fat-1 mammalian models are interesting in that they increase tissue levels of EPA and DHA, the n-3 FA with the most potent biological effects, and levels of their precursor, ␣-linolenic acid. In the fat-1 model, it is possible that conversion of ␣-linolenic acid to EPA and DHA is more efficient than in mammals and humans, in whom conversion is poor. In human studies, DHA intakes of 200 mg/d were required to obtain similar plasma levels of DHA, as reported by Wan et al, 12 whereas increasing intakes of ␣-linolenic acid had virtually no effect on plasma DHA levels. 16 However, humans will not be able to rely on genetic manipulations to increase conversion of n-6 to n-3 FA; rather, they need to rely on diets or supplements rich in EPA and/or DHA to increase n-3 FA levels. For both n-3 and n-6 FA, adequate intake amounts for each are likely to be of higher utility than consideration of the n-6/n-3 ratio. Use of a ratio can disguise extremely low or high intakes of n-6 and/or n-3 FA. 15 Moreover, the specific n-6 and n-3 FA that are represented in calculating an n-6/n-3 ratio are not always clearly defined. Because humans are closer to adequacy for n-6 compared with n-3 FA intakes, at least in most Western populations, the question remains regarding how much n-3 FA intakes should be increased, with the realization that these increases will likely most affect the n-6/n-3 ratio. With the increasing definition of the potential benefits of n-3 FA in growth and development, mental and neural degenerative diseases, inflammatory processes, and perhaps certain forms of cancer, 17 researchers also must determine whether amounts optimal for preventive and therapeutic approaches to coronary heart disease will be applicable to other conditions.
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